Risk factors for delayed initiation of combination antiretroviral therapy in rural north central Nigeria

Journal of Acquired Immune Deficiency Syndromes

Volumn 65, Issue 2, 2014, Pages

  Aliyu, Muktar H ^a   Blevins, Meridith ^a   Parrish, Deidra D ^a   Megazzini, Karen M ^b   Gebi, Usman I ^c   Muhammad, Mukhtar Y ^c   Ahmed, Mukhtar L ^d   Hassan, Adiba ^a,c   Shepherd, Bryan E ^a   Vermund, Sten H ^a   Wester, C William ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b WESTAT   (United States)

^c Friends in Global Health   (Nigeria)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Antiretroviral therapy; HIV AIDS; Implementation science; Mortality; Nigeria; Outcomes; PEPFAR; Retention

Indexed keywords

CD4 ANTIGEN; HEMOGLOBIN;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; EDUCATIONAL STATUS; EMPLOYMENT; FEMALE; FUNCTIONAL STATUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMOBILITY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MARRIAGE; NIGERIA; PRIORITY JOURNAL; PROBABILITY; RISK FACTOR; WORK;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HEALTH SERVICES RESEARCH; HIV INFECTIONS; HUMANS; MALE; NIGERIA; PREGNANCY; RISK FACTORS; RURAL POPULATION; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84893782059     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31829ceaec     Document Type: Article

References (46)

1. UNGASS. 2010 UNGASS country progress report: Nigeria. Available at: http://www.unaids.org/en/dataanalysis/monitoringcountryprogress/ 2010progressreportssubmittedbycountries/Nigeria-UNGASS-2010-Final- Country-Report-20110604.pdf. Accessed February 28, 2012.
2. UNAIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic 2010. New York: Joint United Nations Programme on HIV/AIDS; 2010. Available at: http://www.unaids.org/globalreport/Global-report.htm. Accessed March 08, 2012.
3. WHO/UNAIDS/UNICEF. Global HIV/AIDS Response: Epidemic Update and Health Services Progress Toward Universal Access. Progress Report 2011. Geneva, Switzerland: World Health Organization; 2011. Available at: http://whqlibdoc. who.int/publications/2011/ 9789241502986-eng.pdf. Accessed March 01, 2012.
4. National Agency for the Control of AIDS (NACA). Federal Republic of Nigeria Global AIDS Response. Country Progress Report, Nigeria, GARPR 2012. Abuja, Nigeria; 2012. Available at: http://www.unaids. org/en/dataanalysis/ knowyourresponse/countryprogressreports/2012 countries/ Nigeria%202012%20GARPR%20Report%20Revised.pdf. Accessed September 09, 2012.
5. National Agency for the Control of AIDS (NACA). National HIV/AIDS policy review report. In: Research and New Technologies. Abuja, Nigeria: NACA; 2009. Available at: http://naca.gov.ng/index2.php?option=com-docman&task=doc- view&gid=67&Itemid=268. Accessed October 01, 2012.
6. Aliyu MH, Varkey P, Salihu HM, et al. The HIV/AIDS epidemic in Nigeria: progress, problems and prospects. Afr J Med Med Sci. 2010; 39:233-239.
7. Myer L, Zulliger R, Pienaar D. Diversity of patient preparation activities before initiation of antiretroviral therapy in Cape Town, South Africa. Trop Med Int Health. 2012;17:972-977.
8. Myer L, Zulliger R, Bekker LG, et al. Systemic delays in the initiation of antiretroviral therapy during pregnancy do not improve outcomes of HIVpositive mothers: a cohort study. BMC Pregnancy Childbirth. 2012;12:94.
9. Gebrekristos HT, Mlisana KP, Karim QA. Patients' readiness to start highly active antiretroviral treatment for HIV. BMJ. 2005;331:772-775.
10. Tayler-Smith K, Zachariah R, Manzi M, et al. Demographic characteristics and opportunistic diseases associated with attrition during preparation for antiretroviral therapy in primary health centres in Kibera, Kenya. Trop Med Int Health. 2011;16:579-584.
11. Lawn SD, Myer L, Orrell C, et al. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS. 2005;19:2141-2148.
12. Violari A, Cotton MF, Gibb DM, et al; CHER Study Team. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359:2233-2244.
13. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362: 697-706.
14. Braitstein P, Brinkhof MW, Dabis F, et al; Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration; ART Cohort Collaboration (ART-CC) groups. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817-824.
15. Lawn SD, Harries AD, Anglaret X, et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22:1897-1908.
16. Odafe S, Idoko O, Badru T, et al. Patients' demographic and clinical characteristics and level of care associated with lost to follow-up and mortality in adult patients on first-line ART in Nigerian hospitals. J Int AIDS Soc. 2012;15:17424.
17. Bajunirwe F, Muzoora M. Barriers to the implementation of programs for the prevention of mother-to-child transmission of HIV: a cross-sectional survey in rural and urban Uganda. AIDS Res Ther. 2005;2:10.
18. Aliyu HB, Chuku NN, Kola-Jebutu A, et al. What is the cost of providing outpatient HIV counseling and testing and antiretroviral therapy services in selected public health facilities in Nigeria? J Acquir Immune Defic Syndr. 2012;61:221-225.
19. Federal Ministry of Health, Nigeria (FMOH). National AIDS/STI Control Program. Technical Report. 2010 National HIV Sero-prevalence Sentinel Survey. Abuja, Nigeria: Federal Ministry of Health; 2010. Available at: http://www.nigeria-aids.org/documents/2010-National%20HIV%20Sero% 20Prevalence%20Sentinel%20Survey.pdf. Accessed January 31, 2013.
20. World Health Organization (WHO) HIV/AIDS. Patient Monitoring Guidelines for HIV Care and Antiretroviral Therapy (ART). Geneva, Switzerland: WHO Press; 2006:30-31.
21. Odafe S, Torpey K, Khamofu H, et al. The pattern of attrition from an antiretroviral treatment program in Nigeria. PLoS One. 2012;7:e51254.
22. Omonona BT. Quantitative analysis of rural poverty in Nigeria. In: Nigeria Strategy Support Programme (NSSP) Background Paper 9. Washington, DC: International Food Policy Research Institute; 2009. Available at: http://www.ifpri.org/sites/default/files/publications/nssppb17.pdf.
23. Onoka CA, Uzochukwu BS, Onwujekwe OE, et al. Retention and loss to follow-up in antiretroviral treatment programmes in southeast Nigeria. Pathog Glob Health. 2012;106:46-54.
24. Charurat M, Oyegunle M, Benjamin R, et al. Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors. PLoS One. 2010;5:e10584.
25. Tonwe-Gold B, Ekouevi DK, Viho I, et al. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. PLoS Med. 2007;4:e257.
26. Sturt AS, Dokubo EK, Sint TT. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women. Cochrane Database Syst Rev. 2010;3:CD008440.
27. Iliyasu Z, Abubakar IS, Kabir M, et al. Knowledge of HIV/AIDS and attitude towards voluntary counseling and testing among adults. J Natl Med Assoc. 2006;98:1917-1922.
28. Nwachukwu CE, Odimegwu C. Regional patterns and correlates of HIV voluntary counselling and testing among youths in Nigeria. Afr J Reprod Health. 2011;15:131-146.
29. Stephenson R, Miriam Elfstrom K, Winter A. Community influences on married men's uptake of HIV testing in eight African countries. AIDS Behav. 2013;17:2352-2366.
30. Ugbena R, Aberle-Grasse J, Diallo K, et al. Virological response and HIV drug resistance 12 months after antiretroviral therapy initiation at 2 clinics in Nigeria. Clin Infect Dis. 2012;54:S375-S380.
31. Geng EH, Bangsberg DR, Musinguzi N, et al. Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr. 2010;53:405-411.
32. Chi BH, Yiannoutsos CT, Westfall AO, et al. Universal definition of loss to follow-up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin America. PLoS Med. 2011;8:e1001111.
33. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med. 2011;8:e1001056.
34. Shepherd BE, Blevins M, Vaz LM, et al. Impact of definitions of loss to follow-up on estimates of retention, mortality, and disease progression: application to an HIV program in Mozambique. Am J Epidemiol. 2013;178: 819-828.
35. Jani IV, Sitoe NE, Alfai ER, et al. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study. Lancet. 2011; 378:1572-1579.
36. Zachariah R, Reid SD, Chaillet P, et al. Viewpoint: Why do we need a point-of-care CD4 test for low-income countries? Trop Med Int Health. 2011;16:37-41.
37. HIV Trialists' Collaborative Group. Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. Lancet. 1999;353:2014-2025.
38. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337:725-733.
39. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009;4: e5575.
40. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS. 2004;18:887-895.
41. Ferradini L, Jeannin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006;367:1335-1342.
42. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006;296:782-793.
43. Koethe JR, Blevins M, Bosire C, et al. Self-reported dietary intake and appetite predict early treatment outcome among low-BMI adults initiating HIV treatment in sub-Saharan Africa. Public Health Nutr. 2013;16: 549-558.
44. Koethe JR, Limbada MI, Giganti MJ, et al. Early immunologic response and subsequent survival among malnourished adults receiving antiretroviral therapy in Urban Zambia. AIDS. 2010;24:2117-2121.
45. Koethe JR, Lukusa A, Giganti MJ, et al. Association between weight gain and clinical outcomes among malnourished adults initiating antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr. 2010; 53:507-513.
46. Vermund SH, Sidat M, Weil LF, et al. Transitioning HIV care and treatment programs in southern Africa to full local management. AIDS. 2012;26:1303-1310.